

ALEXION PHARMACEUTICALS INC  
Form 8-K  
November 12, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**  
**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): November 11, 2008**

**ALEXION PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**000-27756**  
(Commission File Number)  
**352 Knotter Drive, Cheshire, Connecticut 06410**

**13-3648318**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

**Registrant's telephone number, including area code: (203) 272-2596**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 11, 2008, Alexion Pharmaceuticals, Inc., or Alexion, announced that David W. Keiser, Alexion's Chief Operating Officer since 1992 and President since 2002, will retire by the end of 2008. Mr. Keiser's responsibilities will be distributed among current members of Alexion's senior management reporting to Leonard Bell, M.D., Chief Executive Officer of Alexion.

Mr. Keiser will remain on Alexion's Board of Directors at least through the expiration of his current term in 2009 and will be available to consult with management and the Board in the future.

A copy of the press release announcing Mr. Keiser's retirement has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on November 11, 2008 relating to the retirement of Mr. David W. Keiser.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: November 12, 2008

By: /s/ Thomas I.H. Dubin

Name: Thomas I. H. Dubin

Title: Senior Vice President and General Counsel